AI in Nonclinical Reporting: From Hype to Real Workflow

Where AI Is Actually Delivering in Nonclinical Reporting

The pharmaceutical industry has spent three years hearing that artificial intelligence will transform drug development. Some of those promises are overdue for a reality check. But in one specific, high-value area, AI in nonclinical reporting is moving from pilot project to genuine production workflow faster than most professionals expected.

The evidence is hard to ignore. Between 2018 and 2023, the FDA’s Center for Drug Evaluation and Research tracked AI-containing drug submissions grow from just 3 to more than 170 per year. In January 2025, the FDA published its first formal draft guidance on how sponsors should use AI to support regulatory decision-making across the nonclinical, clinical, and post-marketing phases of drug development. That guidance is not a caution flag. It is a signal that the agency is preparing its review infrastructure for a world in which AI-generated nonclinical data is routine.

This article cuts through the noise. It explains precisely where AI fits in the nonclinical reporting workflow today, what the regulatory expectations look like, what real implementations are delivering, and where the genuine risks remain. If you work in regulatory affairs, preclinical science, or CRO project management, this is the practical picture you need right now.

What Is Nonclinical Reporting?

Before examining how AI applies, it helps to establish a clear baseline of what nonclinical regulatory reporting actually involves.

Nonclinical reporting refers to the documentation of all preclinical studies conducted to establish a drug candidate’s safety, pharmacokinetics, pharmacodynamics, and toxicological profile before and during human clinical trials. These reports form the backbone of major regulatory submissions including Investigational New Drug (IND) applications, New Drug Applications (NDAs), and Biologics License Applications (BLAs).

Within the electronic Common Technical Document (eCTD) framework, nonclinical content lives in two primary locations. Module 2.4 contains the Nonclinical Overview, a critical synthesis document that integrates findings across all nonclinical studies into a coherent safety narrative. Module 4 contains the individual nonclinical study reports covering pharmacology, pharmacokinetics, and toxicology, each documented according to ICH M4S(R2) guidelines.

The work is demanding. A single nonclinical study report for a 90-day rat toxicology study can run to hundreds of pages. It must integrate raw histopathology data, clinical pathology results, toxicokinetic parameters across multiple dose groups, gross pathology observations, and organ weight data into a structured narrative that regulatory reviewers at the FDA, EMA, or PMDA can assess with confidence. Multiply this across an IND-enabling package for a novel small molecule, and the documentation burden becomes enormous.

This is exactly the environment where AI automation is beginning to demonstrate measurable value. At PointCross, our Xbiom Nonclinical Platform was built precisely to address this bottleneck, automating study report generation and SEND dataset production from a single governed data stream.

Where AI Fits in the Nonclinical Reporting Workflow

AI in nonclinical regulatory writing is not a single technology. It is a set of capabilities applied at different stages of the reporting process. Understanding the distinct roles helps avoid the common mistake of treating AI as a monolithic solution.

Data Extraction and Compilation

The first bottleneck in nonclinical report generation is data aggregation. Study data arrives from multiple sources: SEND-formatted SDTM datasets, laboratory information management systems (LIMS), digital pathology platforms, and legacy spreadsheets. AI-powered data extraction tools can now parse structured datasets, identify dose-group findings, pull toxicokinetic parameters, and flag target organ signals at a fraction of the manual time.

PointCross’s Xbiom Smart Transformer uses machine learning to normalize and harmonize data from disparate LIMS and non-LIMS sources into a unified, analysis-ready model. Each data point retains bi-directional traceability back to its as-collected source, a requirement that is no longer optional under FDA technical conformance guidelines.

Automated First-Draft Generation

Large language models fine-tuned on pharmaceutical and regulatory content can now produce structured first drafts of nonclinical narrative sections. Given SDTM datasets and prior report templates, these systems generate dose-group finding summaries, target organ identification narratives, and mechanistic discussion sections in a format aligned with eCTD expectations.

The Society of Toxicologic Pathology’s 2025 roundtable on agentic AI, held during their Annual Meeting in Chicago, confirmed that this is no longer a research concept. Leading pathologists and CRO scientists reported active evaluation of multi-agent systems capable of coordinating data integration and narrative generation within validated environments.

Xbiom’s AI-LLM drafting capability generates draft report text and summary tables directly from annotated study signals within a CFR Part 11-compliant environment. Study Directors review, edit, and approve all AI-generated content before finalization, preserving the human accountability that regulators require.

Safety Margin Table Generation

Calculating safety margins from toxicokinetic exposure data is a precise, calculation-heavy task that historically required significant manual effort. AI systems can now automate this process, pulling AUC and Cmax values from TK datasets, comparing them to anticipated human clinical exposures, and generating formatted safety margin tables required in Module 2.4. Precision-engineered tables with cross-species comparisons now represent one of the clearest efficiency wins in AI-assisted nonclinical overview generation.

Quality Control and Cross-Reference Checking

Inconsistencies between individual study reports and the integrated nonclinical overview are a persistent source of regulatory queries. AI-powered QC tools can automatically cross-check numerical values, finding descriptions, and terminology across documents, flagging discrepancies before submission. PointCross’s eDataValidator (eDV) performs automated validation of both SEND datasets and SDTM/ADaM packages against FDA and PMDA conformance standards, catching errors that manual review often misses.

Submission Formatting and eCTD Readiness

The final stage involves converting AI-generated content into eCTD-compliant formatted documents ready for submission to the FDA, EMA, or PMDA. PointCross’s single-track processing workflow simultaneously generates the Study Report and submission-ready SEND dataset from one governed data source, eliminating the relay-race handoff between reporting and SEND preparation that has traditionally added weeks to submission timelines.

What the FDA’s 2025 Guidance Actually Says

The FDA’s January 2025 draft guidance titled “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products” is the most consequential regulatory document in this space to date. Regulatory professionals working with AI-assisted nonclinical reporting need to understand its scope, framework, and limits clearly.

What Is in Scope

The guidance covers AI models used across the drug product lifecycle where the model’s output is intended to support a regulatory decision about safety, effectiveness, or quality. For nonclinical reporting, this explicitly includes AI models that predict toxic risk from in vitro data, assist in designing animal studies, generate toxicokinetic analyses, or produce safety summaries that appear in an IND or NDA submission.

What Is Excluded

The guidance carves out two categories. First, AI used in drug discovery, meaning target identification, virtual screening, and lead optimization, is not covered because these outputs do not directly enter regulatory submissions. Second, AI used to streamline internal operations is excluded when those activities do not directly affect patient safety, drug quality, or study reliability. Sponsors should not interpret this as a reason to bypass best practices for AI-generated regulatory content.

The Credibility Assessment Framework

The core mechanism of the guidance is a risk-based credibility assessment framework centered on the concept of a Context of Use (COU). Sponsors must define the specific regulatory purpose for which an AI model’s output will be used, assess the model’s influence on the submission relative to the potential for patient harm, and compile credibility evidence demonstrating the model is fit for that purpose.

The practical output of this process is a credibility assessment plan and a credibility assessment report, both of which sponsors should prepare alongside their regulatory submissions.

In January 2026, the FDA followed the draft guidance with the “Guiding Principles of Good AI Practice in Drug Development,” signaling the agency’s intent to build a durable regulatory framework. The EMA and FDA have jointly developed 10 guiding principles for AI in drug and biological product development, reflecting coordinated international expectations.

According to CenterWatch’s regulatory analysis, the guidance specifically enables AI to reduce the number of nonclinical pharmacokinetic, pharmacodynamic, and toxicologic studies required, a potential shift with profound implications for drug development timelines and animal use.

A Real Workflow: From Data to Submission-Ready Nonclinical Overview

Here is a step-by-step illustration of how a production AI workflow handles nonclinical overview automation for a Module 2.4 document using PointCross’s Xbiom platform:

Step 1: Data Ingestion

Structured SDTM/ADaM datasets, prior GLP study reports, LIMS exports, and toxicokinetic summaries are ingested into Xbiom’s unified governed data model. Protocol, facility, and as-collected data establish a single source of truth.

Step 2: Multi-Species Data Extraction

The AI engine parses datasets across species (rat, dog, monkey) and study durations, extracting dose-group findings, NOAEL determinations, organ weight data, histopathology grades, and clinical pathology trends. Each data point is tagged to its source for full lineage tracking.

Step 3: Narrative Drafting

Xbiom’s AI-LLM capability generates structured narrative drafts for each nonclinical domain: pharmacology, pharmacokinetics, single-dose toxicity, repeat-dose toxicity, genotoxicity, and reproductive toxicity. Section structure and terminology follow regulatory expectations for the target agency.

Step 4: Safety Margin Calculation

Automated tables calculate safety margins from toxicokinetic parameters against anticipated human clinical exposure at the proposed starting dose. Cross-species comparisons are auto-formatted and citation-linked to source data.

Step 5: Study Director and Pathologist Review

A qualified Study Director and toxicologic pathologist review all AI-generated narratives, correct interpretation where needed, and approve the final content. This human review step is required under GLP principles and the FDA’s credibility assessment expectations.

Step 6: Simultaneous eCTD and SEND Output

The approved document and SEND dataset are generated simultaneously from the same governed data stream, with full bi-directional traceability from as-collected source data through to the final regulatory submission. Both deliverables are produced within 2 to 3 weeks after data lock.

Manual vs. AI-Assisted Nonclinical Reporting: A Comparison

Factor	Manual Approach	AI-Assisted Approach
Module 2.4 drafting time	4 to 8 weeks	3 to 7 days
SEND dataset production	Separate workflow, 4 to 6 weeks	Simultaneous with Study Report
Data extraction accuracy	Variable, human error possible	Consistent, source-cited
Safety margin table generation	Manual calculation	Automated from TK datasets
Cross-document consistency	Manual QC required	Automated cross-referencing
Regulatory formatting	Writer-dependent	Template-enforced
Cost per study	High, senior writer time	30 to 50 percent lower at scale
Regulatory acceptance	Established	Evolving, credibility docs required

Ready to see this workflow in action? Watch our on-demand webinar: Automating Study Report and SEND Integration in Nonclinical Safety Studies to see Xbiom’s single-track processing demonstrated live.

Challenges and Limitations: The Honest Assessment

No honest account of AI in preclinical regulatory submissions omits the genuine barriers that remain.

Model interpretability is the most fundamental scientific concern. Many high-performing AI models function as black boxes, producing outputs that cannot be traced to a step-by-step reasoning process. Regulatory agencies require explainability. As researchers at Johns Hopkins and the University of Konstanz have noted in peer-reviewed assessments of AI in toxicology, explainable AI (xAI) methods are advancing but have not yet fully solved this problem for complex toxicological prediction models.

Training data quality and bias are persistent risks. AI models trained on historical nonclinical datasets inherit any systematic biases in those datasets, including species-selection biases, assay variability, and reporting inconsistencies across laboratories. A model trained predominantly on small molecule data may perform poorly on biologic candidates.

Adoption remains limited. A global assessment conducted by the Tufts Center for the Study of Drug Development and the Drug Information Association found that only 11 percent of pharmaceutical and CRO companies have fully implemented AI or machine learning solutions in drug development. Roughly two-thirds of respondents reported low confidence in the accuracy of AI-generated data.

Cost is a real barrier for smaller organizations. The average investment to implement an AI-enabled regulatory workflow exceeds one million US dollars. This is accessible for large pharma but challenging for early-stage biotechs. PointCross addresses this through a SaaS delivery model for Xbiom, allowing smaller sponsors and CROs to access validated AI reporting capabilities without the capital expense of an in-house build.

Regulatory uncertainty has not fully resolved. The FDA’s 2025 draft guidance remains in draft form and has not yet been finalized. Sponsors submitting AI-generated nonclinical content are operating in an environment where agency reviewers are still developing their own internal expertise for evaluating credibility assessment reports. Legal analysis from the Food and Drug Law Institute highlights that compliance strategies must evolve as the regulatory framework matures.

The Global Regulatory Landscape

The FDA is the most advanced agency in articulating AI-specific guidance for drug development, but it is not the only agency shaping this space.

The European Medicines Agency (EMA) has engaged stakeholders on AI use in regulatory submissions and co-developed 10 shared guiding principles with the FDA for AI in drug and biological product development, signaling regulatory convergence on transparency, accountability, and model validation. A comparative analysis of global AI regulatory frameworks published in mid-2025 provides a detailed breakdown of how FDA, EMA, MHRA, PMDA, and Swissmedic are each approaching this challenge.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published a high-level AI regulatory strategy aligned with five principles derived from the UK government’s 2023 AI White Paper: safety, robustness, transparency, fairness, and accountability.

The PMDA in Japan has shown openness to AI-assisted submissions. PointCross’s Xbiom platform generates eCTD-formatted outputs that meet PMDA technical conformance requirements, allowing sponsors to target simultaneous global submissions without additional reformatting.

The World Health Organization has separately emphasized that AI systems in healthcare must be clinically validated, socially equitable, and governed with clear accountability structures. For sponsors, this translates to a practical requirement: document your AI governance before your first AI-assisted submission, not after.

What This Means for CROs, Biotechs, and Pharma Teams

The practical implications differ depending on where you sit in the drug development ecosystem.

For large pharmaceutical companies, the ROI case is compelling. The Tufts CSDD assessment found an average 18 percent cycle time reduction across AI-enabled regulatory activities, with the highest time savings in regulatory documentation preparation. At scale, this translates directly to accelerated IND filing timelines. PointCross’s single-track processing has demonstrated 40 to 60 percent cost reductions per nonclinical study, and reduces the sequential Study Report plus SEND timeline by 2 to 4 weeks, a gain that compounds across a multi-study IND package.

For CROs, AI-assisted nonclinical reporting is becoming a competitive differentiator. CROs that integrate validated AI reporting tools can deliver faster turnaround on Module 2.4 documents and IND packages without proportionally increasing headcount. PointCross is already trusted by more than 400 sponsor and CRO customers annually, and our SEND services and nonclinical data management are built for CRO operating models.

For early-stage biotechs, the most accessible entry point is partnering with a technology provider that has already built and validated an AI reporting workflow. The capital and time investment for an internal build is rarely justified until a company has multiple simultaneous IND-enabling programs.

Three practical recommendations for any team considering AI-assisted nonclinical reporting:

Start with a single study type, such as a 28-day rat toxicology study, validate AI-generated outputs against a previously submitted report, and document the comparison before using AI outputs in a live submission.
Build a credibility assessment plan before your next IND, even if AI use is currently limited. Establishing the documentation habit now reduces friction as AI use expands.
Ensure that a qualified Study Director or toxicologic pathologist reviews every AI-generated narrative before it enters a submission. Human oversight is both a regulatory expectation and a scientific necessity.

Frequently Asked Questions: AI in Nonclinical Reporting

What is AI nonclinical reporting in drug development?

AI nonclinical reporting refers to the use of artificial intelligence tools, including large language models and machine learning systems, to automate or assist in the generation of preclinical study reports and regulatory submission documents. These tools extract data from structured datasets, generate narrative drafts, calculate safety margins, and format outputs for eCTD submission. Human expert review remains a required component of any compliant workflow.

Does the FDA accept AI-generated nonclinical study reports?

The FDA has not prohibited AI-generated nonclinical content. Its January 2025 draft guidance establishes a credibility assessment framework that sponsors must follow when AI-generated data or information is used to support a regulatory decision about safety, effectiveness, or quality. Sponsors using AI to generate nonclinical summaries should prepare a credibility assessment plan documenting the model’s context of use, risk level, and validation evidence.

What is the FDA’s 2025 AI guidance for nonclinical studies?

The FDA’s 2025 draft guidance applies to AI models used across the drug product lifecycle, including nonclinical pharmacokinetic, pharmacodynamic, and toxicology studies. It introduces a risk-based credibility assessment framework requiring sponsors to define a specific context of use, assess model influence and risk, and compile evidence that the model is fit for its regulatory purpose. Drug discovery applications and purely operational AI tools are excluded from scope.

How does agentic AI work in toxicology reporting?

Agentic AI systems for toxicology reporting use multiple coordinated AI agents, each handling a specific task. One agent extracts and structures data from SDTM datasets, another generates narrative text for specific report sections, a third performs cross-reference checking for consistency, and a formatting agent converts the output into eCTD-compliant document structure. A qualified toxicologic pathologist reviews and approves the final output before submission. The STP 2025 white paper on agentic AI in toxicologic pathology provides a detailed technical overview of this architecture.

What is eCTD Module 2.4 and can AI generate it?

eCTD Module 2.4 is the Nonclinical Overview section of the electronic Common Technical Document, accepted by the FDA, EMA, PMDA, and other major health authorities. It integrates findings from all nonclinical studies into a coherent safety narrative. AI systems including PointCross’s Xbiom platform can generate structured first drafts of Module 2.4, including safety margin tables and multi-species summary narratives, with both the Study Report and SEND dataset produced simultaneously from a single governed data source.

What are the risks of using AI in preclinical regulatory submissions?

The primary risks include model interpretability limitations, training data bias, regulatory acceptance uncertainty, and data governance concerns around proprietary study data. A 2025 peer-reviewed analysis in Frontiers in Toxicology outlines a framework for AI risk assessment in regulatory science. Human expert review at key stages is essential to mitigating these risks in any compliant nonclinical AI workflow.

Which AI tools are used for nonclinical regulatory writing?

Currently deployed tools include PointCross’s Xbiom Nonclinical Platform for study-data-integrated report drafting and simultaneous SEND production, as well as platforms like Benchling AI and Certara’s generative AI regulatory writing tools. Each platform has different strengths in data integration, output formatting, and regulatory compliance features.

How long does it take AI to generate a nonclinical overview?

Published timelines report AI-assisted Module 2.4 generation in three to seven working days for well-structured programs, compared to four to eight weeks for a manual approach. PointCross’s single-track processing delivers both the Study Report and submission-ready SEND dataset within 2 to 3 weeks after data lock, with 30 to 50 percent cost savings per study compared to the traditional sequential approach.

What is a credibility assessment framework in AI drug development?

A credibility assessment framework is the structured process the FDA expects sponsors to follow when using AI models to generate data for regulatory submissions. It requires sponsors to define the model’s Context of Use, assess risk based on the model’s influence and potential for harm, gather evidence of model performance in that specific context, and document the entire process in a credibility assessment report. The framework is adapted from established model credibility concepts in engineering and computational science.

Can small biotech companies afford AI for regulatory writing?

Building an internal AI reporting capability requires average investments exceeding one million US dollars, which is prohibitive for most early-stage biotechs. PointCross addresses this through its SaaS delivery model, allowing smaller sponsors to access validated AI nonclinical reporting without the capital overhead of an in-house build. Contact our team to discuss how Xbiom can be scoped to your program size and submission timeline.

Conclusion

AI in nonclinical reporting has moved past the hype phase. The evidence from production deployments, regulatory guidance, and adoption research tells a consistent story: AI is delivering real efficiency gains in study report generation, safety margin calculation, data extraction, SEND production, and QC workflows. It is doing this within a regulatory environment that is actively, if carefully, accommodating its use.

What has not changed is the central role of qualified scientists. The Study Director reviewing AI-generated narratives, the toxicologic pathologist validating histopathology interpretations, and the regulatory affairs professional ensuring credibility documentation is in order are not being replaced. They are being freed from the most time-consuming manual stages of reporting so they can focus on scientific judgment and regulatory strategy.

For CROs, biotechs, and pharma teams ready to move from hype to workflow, the foundation is available now. The regulatory framework is in place, the tools are in production, and the first-movers are already delivering faster, more consistent nonclinical submissions.

The question is no longer whether AI belongs in nonclinical reporting. It is whether your organization is building the process to use it responsibly.

Take the Next Step with PointCross

PointCross Life Sciences has been trusted by more than 500 sponsor and CRO organizations annually to deliver submission-ready nonclinical data, SEND datasets, and study reports. The Xbiom platform now brings AI-assisted drafting, simultaneous SEND generation, and validated eCTD formatting into a single, CFR Part 11-compliant workflow.

Explore what Xbiom can do for your next IND-enabling program:

References

[1] U.S. Food and Drug Administration. (January 2025). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (Draft Guidance). https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development

[2] U.S. Food and Drug Administration. (January 2026). Guiding Principles of Good AI Practice in Drug Development. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development

[3] Rajpoot, N. et al. (2025). Potential Role of Agentic Artificial Intelligence in Toxicologic Pathology. Society of Toxicologic Pathology Annual Meeting White Paper. https://arxiv.org/pdf/2602.06980

[4] Teunis, M., Luechtefeld, T., and Hartung, T. (2025). Leveraging artificial intelligence and open science for toxicological risk assessment. Frontiers in Toxicology. DOI: 10.3389/ftox.2025.1568453. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861075/

[5] Hartung, T. (2025). Navigating the AI Frontier in Toxicology: Trends, Trust, and Transformation. Current Environmental Health Reports. https://link.springer.com/article/10.1007/s40572-025-00514-6

[6] Hartung, T. (2025). AI, agentic models and lab automation for scientific discovery. Frontiers in Artificial Intelligence. DOI: 10.3389/frai.2025.1649155. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426084/

[7] Tufts Center for the Study of Drug Development and Drug Information Association. (2024-2025). Global assessment of AI/ML adoption and impact in drug development. Applied Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/new-insights-on-the-impact-of-ai-enabled-solutions

[8] AI in pharmacovigilance: a narrative review. (2025). PubMed Central. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335403/

[9] CenterWatch. (2025). The Role of AI in Regulatory Decision-Making for Drugs and Biologics. https://www.centerwatch.com/insights/the-role-of-ai-in-regulatory-decision-making-for-drugs-biologics-the-fdas-latest-guidance/

[10] p05.org. (July 2025). Comparative Regulatory Approaches to AI in Drug Development. https://www.p05.org/comparative-regulatory-approaches-to-ai-in-drug-development-as-of-july-2025/

[11] Food and Drug Law Institute. (July 2025). Regulating the Use of AI in Drug Development: Legal Challenges and Compliance Strategies. https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/

[12] PointCross Life Sciences. (December 2025). Revolutionary Single-Track Process Transforms Nonclinical Data Management. https://pointcrosslifesciences.com/revolutionary-single-track-process-transforms-nonclinical-data-management/

This article is for informational purposes for regulatory affairs professionals and pharmaceutical scientists. It does not constitute legal or regulatory advice. Consult your regulatory affairs team and legal counsel before making submission decisions based on information contained here.